The text discusses various studies on the use of circulating tumor DNA (ctDNA) as a prognostic and predictive marker for adjuvant treatment duration and decision-making in stage II colon cancer. It also explores the efficacy of adjuvant therapy in colon cancer, including the use of FOLFOX4 and targeted next-generation sequencing of ctDNA for tracking minimal residual disease.